Introduction

Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011 guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances and modifications in the treatment of advanced metastatic disease is only briefly dealt with here as it is covered in a separate paper in this issue, similar to the 2011 guideline format [3]. The format used here is the same as that used in the 2011 guidelines with page references to the appropriate paper inserted [1, 2]. This document is meant as a supplement to these guidelines and does not reiterate all of the points made in the previous guidelines, only changes, supporting findings or modifications of the 2011 guidelines are thus covered here.

As in the previous functional pancreatic neuroendocrine tumor (F-P-NET) guidelines [1], the F-P-NETs will be considered in three groups: the more frequent gastrinomas and insulinomas considered independently and all the rare F-P-NETs (RFTs) considered together and as a separate category (Appendix 1 and table 1).

Most P-NETs occur as sporadic tumors (non-inherited), although a variable proportion of the different F-P-NETs occurs as part of an inherited syndrome. MEN1 remains the most important inherited condition responsible for 20–30% of gastrinomas and <5% of insulinomas or RFTs [4–7]; and uncommon causes of inherited P-NETs include von Hippel Lindau disease (VHL), von Recklinghausen's syndrome (neurofibromatosis 1) and tuberous sclerosis [4, 5]. In each of the latter inherited
disorders, the patients only rarely develop F-P-NETs, with 10–17% of VHL patients developing a non-functional (NF)-P-NET, <10% of neurofibromatosis 1 patients developing a P-NET, which is almost always a somatostatinoma (SSoma) of the duodenum, which is rarely functional; and patients with tuberous sclerosis only rarely (<1%) develop a F-P-NET or NF-P-NET [4]. Other rarer syndromes with a possible genetic link are discussed in Appendix 1.

Epidemiology and Clinicopathological Features

The frequency of F-P-NETs, similar to that of NF-P-NETs, and all gastrointestinal NETs [8, 9] continues to be reported to be increasing in a number of countries [9–13]. In some recent series, between 60 and 90% of P-NETs are NF, these are generally diagnosed at more advanced stages because of their relatively indolent nature and slow growth causing a delay in the onset of symptoms. However, there is also an exponential increase of incidental diagnoses of NF-P-NETs which are becoming frequent with the widespread use of high-quality imaging techniques [14–16].

In general, the RFTs and very rare F-P-NETs listed in table 1 have sufficient numbers of cases or sufficient descriptions of small numbers of cases to verify that they should be considered as established F-P-NET syndromes [17, 18]. A possible exception to this is the case of SSomas. Recently, the actual existence of a distinct clinical SSoma syndrome has been questioned because in one extensive review of cases, none of the 46 patients with pathologically diagnosed SSomas, nor any of 821 other P-NET cases reviewed, had the full features of the proposed clinical SSoma syndrome [19].

A small percentage of patients with gastric acid hypersecretion and clinical features of Zollinger-Ellison syndrome (ZES) are found to have normal fasting serum gastrin (FSG) levels and negative secretin tests [20–22], and in light of the features of the patient recently described with a P-NET secreting cholecystokinin (CCKoma) [23], these patients should have their plasma CCK levels assessed. This may be difficult at present because only a few groups have proven assays, and recent studies demonstrate that many commercial laboratories use poorly characterized antibodies even for such frequent assays as the assessment of serum gastrin levels [24, 25].

Prognosis and Survival in Sporadic F-P-NETs and NF-P-NETs

Numerous studies have described molecular changes in P-NETs that correlate with prognosis, in most cases not distinguishing the type of P-NET syndrome. This will be considered in a later section on the histopathology and genetics of F-P-NETs. In addition to the prognostic factors described in the previous guidelines [1], recent papers have described further prognostic factors. These include:

a) the demonstration that the presence of calcifications on preoperative CT scans in patients with P-NETs (which occurs in 16%) correlates with the grade and the presence of lymph node metastasis in well-differentiated P-NETs [26];

b) the demonstration that the extent of liver metastasis either unilobar or bilobar or the presence of extra-abdominal metastasis is an important predictor of survival independent of the tumor grading (Ki-67 index) [27];

c) most patients with advanced P-NET progress over time, and the best prognosticator for progression was the Ki-67 index [28];

d) a number of studies now report that in P-NET patients the presence of positive lymph nodes and their number have important prognostic value [29–36]. These results support the recommendation that a systematic removal of lymph nodes in the peritumoral area should be part of any P-NET operation. However, in the case of lymph node involvement, both the positive nodal status on its own and the number of lymph nodes involved, as well as the ratio between positive lymph nodes and total examined lymph nodes, are important predictors of recurrence after surgery [29, 30]. This will be further discussed in the therapy section below;

e) in one study, the absence of symptoms was associated with a significantly better outcome despite the tumour stage [28]. Since the incidental diagnoses of P-NETs is becoming more frequent, especially in the case of NF-P-NETs, with the widespread use of high-quality imaging techniques, this figure can have an impact on therapeutic choice [37, 38].

Numerous recent studies have established the importance of the different classification and grading systems for P-NETs and other NETs that have been proposed (WHO 2010, ENETS, AJCC/UICC) [9, 39, 40]. In several studies [39, 41–44], both the classification and grading have prognostic value, in most cases as an independent variable on multivariate analysis; and therefore it is essential not only for the proper treatment strategy, but also
for the prognostic value, that in all F-P-NET patients, proper staging, tumor classification and grading should be performed [9, 39, 40].

As will be discussed in the histopathology section below, a number of molecular changes have been described which, although still not used generally clinically, have prognostic significance – for example, chromosome instability as a consequence of loss of some genes (DAXX or ATRX) has been shown to correlate with a worse survival [45].

Table 1. F-P-NET syndromes

<table>
<thead>
<tr>
<th>Name</th>
<th>Biologically active peptide(s) secreted</th>
<th>Incidence (new cases/10^6 population/year)</th>
<th>Tumor location</th>
<th>Malignant, %</th>
<th>Associated with MEN-1, %</th>
<th>Main symptoms/signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The most common F-P-NET syndromes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulinoma</td>
<td>Insulin</td>
<td>1 – 32</td>
<td>Pancreas (&gt;99%)</td>
<td>&lt;10</td>
<td>4 – 5</td>
<td>Hypoglycemic symptoms (100%)</td>
</tr>
<tr>
<td>ZES</td>
<td>Gastrin</td>
<td>0.5 – 21.5</td>
<td>Duodenum (70%) Pancreas (25%) Other sites (5%)</td>
<td>60 – 90</td>
<td>20 – 25</td>
<td>Pain (79 – 100%) Diarrhea (30 – 75%) Esophageal symptoms (31 – 56%)</td>
</tr>
<tr>
<td><strong>Established RFT syndromes (&gt;100 cases)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VIPoma (Verner-Morrison syndrome, pancreatic cholera, WDHA)</td>
<td>Vasoactive intestinal peptide</td>
<td>0.05 – 0.2</td>
<td>Pancreas (90%, adult) Other (10%, neural, adrenal, periganglionic)</td>
<td>40 – 70</td>
<td>6</td>
<td>Diarrhea (90 – 100%) Hypokalemic (80 – 100%) Dehydration (83%)</td>
</tr>
<tr>
<td>Glucagonoma</td>
<td>Glucagon</td>
<td>0.01 – 0.1</td>
<td>Pancreas (100%)</td>
<td>50 – 80</td>
<td>1 – 20</td>
<td>Rash (67 – 90%) Glucose intolerance (38 – 87%) Weight loss (66 – 96%)</td>
</tr>
<tr>
<td>SSoma</td>
<td>Somatostatin</td>
<td>Rare</td>
<td>Pancreas (55%) Duodenum/jejenum (44%)</td>
<td>&gt;70</td>
<td>45</td>
<td>Diabetes mellitus (63 – 90%) Cholelithiasis (65 – 90%) Diarrhea (35 – 90%)</td>
</tr>
<tr>
<td>GRHoma</td>
<td>Growth hormone-releasing hormone</td>
<td>Unknown</td>
<td>Pancreas (30%) Lung (54%) Jejunum (7%) Other (13%)</td>
<td>&gt;60</td>
<td>16</td>
<td>Acromegaly (100%)</td>
</tr>
<tr>
<td>ACTHoma</td>
<td>ACTH</td>
<td>Rare</td>
<td>Pancreas (4 – 16% all ectopic Cushing’s syndrome)</td>
<td>&gt;95</td>
<td>Rare</td>
<td>Cushing’s syndrome (100%)</td>
</tr>
<tr>
<td>P-NET causing carcinoid syndrome</td>
<td>Serotonin (?) Tachykinins</td>
<td>Rare (43 cases)</td>
<td>Pancreas (&lt;1% all carcinoids)</td>
<td>60 – 88</td>
<td>Rare</td>
<td>Same as carcinoid syndrome above</td>
</tr>
<tr>
<td>P-NET causing hypercalcemia (PTHrPoma)</td>
<td>PTHrP Others unknown</td>
<td>Rare</td>
<td>Pancreas (rare cause of hypercalcemia)</td>
<td>84</td>
<td>Rare</td>
<td>Abdominal pain due to hepatic metastases</td>
</tr>
<tr>
<td><strong>Very rare F-P-NET syndromes (1 – 5 cases)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-NET secreting renin</td>
<td>renin</td>
<td>Rare</td>
<td>Pancreas</td>
<td>Unknown</td>
<td>No</td>
<td>Hypertension</td>
</tr>
<tr>
<td>P-NET secreting luteinizing hormone</td>
<td>Luteinizing hormone</td>
<td>Rare</td>
<td>Pancreas</td>
<td>Unknown</td>
<td>No</td>
<td>Anovulation Virilization (female)/reduced libido (male)</td>
</tr>
<tr>
<td>P-NET secreting erythropoietin</td>
<td>Erythropoietin</td>
<td>Rare</td>
<td>Pancreas</td>
<td>100</td>
<td>No</td>
<td>Polycythemia</td>
</tr>
<tr>
<td>P-NET secreting insulin-like growth factor 2</td>
<td>Insulin-like growth factor II</td>
<td>Rare</td>
<td>Pancreas</td>
<td>Unknown</td>
<td>No</td>
<td>Hypoglycemia</td>
</tr>
<tr>
<td>P-NET secreting CCK (CCKoma)</td>
<td>CCK</td>
<td>Rare</td>
<td>Pancreas</td>
<td>Unknown</td>
<td>No</td>
<td>Diarrhea Ulcer disease Weight loss Cholelithiasis</td>
</tr>
<tr>
<td>P-NET secreting GLP-1</td>
<td>GLP-1</td>
<td>Rare</td>
<td>Pancreas</td>
<td>Unknown</td>
<td>No</td>
<td>Hypoglycemia</td>
</tr>
</tbody>
</table>

VIP = Vasoactive intestinal peptide; WDHA = watery diarrhea, hypokalemia, achlorhydria; PTHrP = parathyroid hormone-related peptide.
**Prognosis and Survival in F-P-NET Patients within MEN1**

As stated in this section of the 2011 guidelines [1], the current prognosis of MEN1 patients with P-NETs remains unclear. This is in large part because of the marked effectiveness of treatment for F-P-NETs within MEN1 (40–60% ZES, 20–30% insulinomas, <5% remaining RFTs) [4, 5, 7]. Prior to the development of effective medical therapies, gastric acid hypersecretion due to ZES was the main cause of death in MEN1 patients in most series, whereas at present, it can be controlled in all patients and is no longer a cause of death [4, 5, 22, 46]. Furthermore, renal failure due to uncontrolled hyperparathyroidism and hormone-excess states due to pituitary tumors and other F-P-NET syndromes are no longer a frequent cause of death in MEN1 patients [4, 5, 22, 46]. Recently, important information on the natural history and prognostic factors of MEN1 patients with ZES (MEN1/ZES) has been provided by a large prospective NIH study (n = 106) [5] with a mean follow-up time of 24.5 years; the results were compared to a pooled literature group of 227 MEN1 patients with P-NETs, who did not die of gastric acid hypersecretion, and to 1,386 MEN1 patients in various large MEN1 series (60% had P-NET). In this study, none of the NIH patients died from gastric acid hypersecretion. Among both the NIH patients and the pooled literature series, two thirds of the patients died from an MEN1-related cause, and in 40% the cause of death was due to the P-NET, which was the main cause of death. The second most frequent cause of mortality in MEN1 is due to thymic carcinoids, which occur primarily in men (>90%) and are very aggressive tumors [5, 7, 47–49]. In this study [5], the non-MEN1-related causes of death were reported for the first time with the relative order being cardiovascular disease, other non-MEN1 malignancies (mainly in the lung) and cerebrovascular disease. Important prognostic factors found in this study [5] include the presence of thymic carcinoids, presence of liver or distant metastasis, aggressive P-NET growth, large P-NETs, development of new lesions during follow-up, high levels of tumor markers such as gastrin and the development of other functional P-NET syndromes.

**Clinical Presentation of F-P-NETs**

The clinical features of patients with gastrinomas, ZES and insulinomas have been covered in detail in the previous guidelines [1]. Literature updates included a recent study [50] reporting that 81% of all patients with ZES due to duodenal tumors (60–95% of the ZES patients) had a long-term history of high alcohol use (>50 g/day) and proposed this may be a risk factor for ZES.

Patients with insulinomas characteristically develop symptoms while fasting or during exercise; however, some patients (up to 18%) develop symptoms postprandially and these may be the only symptoms [51–53]. Others have found that with the new guidelines for 72-hour fast results (glucose <55 mg/dl and insulin <3 μU/ml), an insulinoma cannot be excluded in the absence of hypoglycemia, as patients may present with postprandial hypoglycemia following an oral glucose tolerance test. In a single-institutional study, 18% of the patients complained of postprandial symptoms and 21% had previously been affected by diabetes type 2 or impaired glucose tolerance [51]. These data support previous findings that a subset of patients with insulinomas may be diagnosed on the basis of an altered insulin secretory pattern during an oral glucose tolerance test inducing hypoglycemia rather than the classical 72-h fast.

**Diagnosis**

**Diagnosis of ZES**

**General** [1, pp. 102–103] (fig. 1)

Numerous publications support the conclusion that the diagnosis of ZES is becoming more difficult [22, 25, 54–58]. This is occurring because of the increasing unreliability of commercial gastrin assays in many widely used commercial laboratories [24, 25], the lack of availability of secretin used to perform secretin provocative tests [59, 60] and the widespread use of proton pump inhibitors (PPIs) [54–56, 61]. The unreliability of some commercial gastrin assays can be circumvented by either using a reliable laboratory identified in recent publications [24, 25] or by consulting a center of excellence in the diagnosis of ZES [24, 25, 54]. The lack of secretin can be a major problem in some patients, since 60% of all ZES patients present with FSG levels <10-fold the upper limit of normal and with a gastric pH <2, and these features can overlap with many other conditions. Indeed, up to 40% of these patients will not have an identifiable gastrinoma, necessitating a secretin test [20, 21, 54, 56, 60, 62]. Recently, a glucagon provocative test with established criteria for positivity has been proposed as a substitute if secretin is not available [59]; however, with limited data and unclear sensitivity and specificity. The widespread use of PPIs is a major problem for the diagnosis of ZES because these drugs have an extended duration of action (up to one
week), they cause hypergastrinemia in 80–100% of all normal subjects, and thus can confound the diagnosis [22, 54, 56, 57, 61]. Furthermore, if PPIs are abruptly stopped in a true ZES patient, acid-peptic complications can rapidly develop [55, 58], and therefore some expert groups have recently recommended that the diagnosis of ZES should be established without stopping the PPIs or by attempting to taper the dose. Unfortunately, as suggested in a number of recent papers [17, 22, 54, 56], in most patients, the diagnosis cannot be easily established without an interruption of the PPIs. Furthermore, a secretin test cannot be used while a patient is taking PPIs because it can result in a false positive test [60]. Other tumor markers such serum chromogranin A were found to be not reliable for the diagnosis of ZES patients, as up to 30% have normal plasma chromogranin A levels [63]. PPIs also lead to increased chromogranin A levels on their own. It is therefore recommend that if the diagnosis (see below) is unclear (FSG <10-fold increased, gastric pH <2, no tumor imaged), the patient should be referred to a center of excellence and if this is not possible, PPI withdrawal should be cautiously performed (in an asymptomatic patient with no active acid-peptic disease or damage) and with adequate cover by H2 blockers and careful patient monitoring [17, 22, 54, 56] (by in-patient setting or daily checks on an out-patient basis).

**Minimal Consensus Statement on Diagnosis**

**Patients with Gastrinomas and ZES: Biochemistry and Laboratory Studies**

The diagnosis of ZES requires the demonstration of an inappropriately elevated FSG level in the presence of hypergastrinemia when gastric acid secretion is present. This is best accomplished by establishing hypergastrinemia when the gastric pH is
Hypergastrinemia due to another cause than ZES, particularly hypo- or achlorhydria secondary to other conditions (atrophic gastric, pernicious anemia, *Helicobacter pylori* infections) or the use of PPIs, is much more frequent than ZES and cannot be excluded by assessing fasting gastrin levels alone or by a secretin provocative test. Thus an assessment of gastric secretion measuring the gastric pH is required [22, 54, 56, 58, 60].

If the FSG level is >10-fold the normal value and the gastric pH is <2, a diagnosis of ZES is established (40% of all ZES patients); however, in the remaining 60% of the ZES patients, the FSG level is <10-fold elevated with a gastric pH <2 [20], so additional testing is needed [1]. In patients taking PPIs where ZES is suspected, reaching a diagnosis is not a matter of emergency and should be undertaken only when the patient is stable and free of acid-peptic disease, additionally, the PPIs should not be abruptly stopped [17, 54–57]. Referral to a center of excellence is more important. If this is not possible, an attempt to reduce the PPI dose and frequency, while monitoring the gastric pH, can be undertaken, with adequate coverage by high doses of H2 blockers and careful patient monitoring [17, 22, 54, 56].

Patients with ZES, Insulinomas (fig. 2) or RFT-Specific MEN1

Despite numerous guidelines [7], the diagnosis of MEN1 in patients with a F-P-NET or in the presence of F-P-NETs is frequently markedly delayed (5–9.5 years) [5, 65]. A recent study assessed the risk factors of an ulterior diagnosis of MEN1 in patients with sporadic NETs [66]. In this study, 16% were found to have MEN1, the risk factors included: recurrent primary hyperparathyroidism [odds risk (OR) 162.4]; non-recurrent hyperparathyroidism (OR 26); the presence of a P-NET, a duodenal NET (OR 18) or a pituitary tumor (OR 4.7), or a positive family history of NET (OR 4.5) [66]. Recent studies confirmed that insulinomas occur earlier in MEN1 patients than gastrinomas and that in 25% of all MEN1 patients insulinomas appear before the age of 20, which is rarely the case with gastrinomas [4, 67–69]. Therefore, if a patient is diagnosed with insulinoma before the age of 20 or with multiple insulinomas at any age, MEN1 should be suspected [17, 67, 69]. As outlined in the 2011 guidelines [1], it is essential that all MEN1 patients are screened for P-NETs, both F and NF, and that this assessment is repeated during follow-up.

Patients with Insulinomas

The exact criteria for the diagnosis of insulinoma continue to evolve and vary in different consensus documents and reviews [70–77]. In a consensus report from the US Endocrine Society [76], the following diagnostic criteria were proposed: endogenous hyperinsulinism documented by the finding of symptoms, signs or both, with plasma concentrations of glucose <55 mg/dl.
(3.0 mmol/l), insulin ≥3.0 μU/ml (18 pmol/l), C-peptide ≥0.6 ng/ml (0.2 nmol/l) and proinsulin ≥5.0 pmol/l. The presence of a plasma β-hydroxybutyrate level of ≤2.7 mmol/l and an increase in plasma glucose of ≥25 mg/dl (1.4 mmol/l) after i.v. glucagon indicated a mediation of the hypoglycemia by insulin (or by an IGF). The use of an insulin cut-off value of ≤3 instead of ≤5 μU/ml is supported by a recent study showing that 9% of all patients with insulinoma would remain undetected with the older recommended value of ≥5 [73]. Another study [72] demonstrated that some patients with insulinoma (23%) can have plasma β-hydroxybutyrate levels of >2.7 mmol/l, especially if they have previously undergone partial pancreatectomy and are being evaluated for recurrence [72]. In contrast to other pNETs, a recent study reported that evaluating serum chromogranin A levels is frequently not helpful for diagnosing patients with insulinoma – an elevated chromogranin A value has only a 73% specificity compared to 92% in non-insulinoma P-NET patients [78].

Diagnosis of NF-P-NETs

Laboratory Tests

Chromogranin A and pancreatic polypeptide were recommended as circulating tumor markers in NF-P-NETs in the previous guidelines. However, the percentage of patients with elevated pancreatic polypeptide levels is lower than that of patients with elevated chromogranin A levels [2].

Measuring chromogranin A can be useful for reaching a diagnosis in a fraction of NF-P-NET patients, and if elevated it is potentially helpful for evaluating treatment response and for detecting progression and recurrence at an early stage. Standardization of a chromogranin A assay is needed [79].

In patients with NF-P-NETs developing hormonal symptoms, the appropriate plasma hormone and peptide concentration that could cause the symptomatology should be assessed, and treatment may need to be changed [2].

Localization

Localization of Tumor and Tumor Extent

While somatostatin receptor scintigraphy (SRS) with SPECT remains useful in staging P-NETs, numerous studies have demonstrated that imaging with positron emission tomography with CT (PET/CT) with 68Ga-labeled somatostatin analogues has the highest sensitivity for localizing P-NETs, as well as generally for other NETs, and also has a high specificity. In various studies on P-NETs, the sensitivity varied from 86 to 100% and the specificity from 79 to 100% for all P-NETs [80–89], except insulinomas, in which case the sensitivity was only 25% [90]. The consequence of these findings is that PET/CT is now the method of choice to fully stage and localize the extent of disease in patients with non-insulinoma P-NETs [83, 91]. 68Ga-labeled somatostatin analogues have been shown to change the management (surgical, medical, staging) in 20–55% of all patients [87, 88, 92, 93] and, therefore, they should generally be used in patients with non-insulinoma P-NETs.

ZES, Other F-P-NET and NF-P-NET Localization

In sporadic ZES, gastrinomas occur in the duodenum in 60–80% of all MEN1/ZES patients, they occur primarily in the duodenum (90–100%) with 0–15% in the pancreas in different series [4, 7, 57, 94–96]. In sporadic ZES, gastrinomas are known to occasionally occur in the liver (<1%) and liver/hepatobiliary system [57, 97–99], which has recently also been demonstrated for MEN1/ZES patients [100]. Gastrinomas in these locations, especially in the duodenum, can be small (<0.5 cm) and multiple, therefore sensitive imaging, especially preoperatively, is mandatory [57, 101, 102]. Recent studies have shown imaging with 68Ga-labeled somatostatin analogues with PET/CT to be highly sensitive and specific for P-NETs, including gastrinomas [80, 103, 104], and NF-P-NETs when evaluating the location and staging the extent of disease [85, 105]. Preoperative staging should therefore at least include SRS and preferably 68Ga-DOTA-TOC/TATE/NOC-PET/CT [2]. 68Ga-labeled somatostatin analogues with PET/CT, if available, should be considered as first-line diagnostic imaging method for staging P-NET patients [83]. If unavailable, SRS/SPECT with endoscopic ultrasound (EUS) and esophagogastroduodenoscopy should be combined. In case of rapid tumor progression in earlier diagnosed G1–G2 tumors, 18FDG-PET/CT may be considered to assess tumor burden and prognosis [106].

Minimal Consensus Statement on MEN1

A recent large prospective study [5] demonstrated that MEN1 patients are living longer than in the past; however, their life expectancy is still shortened (with a mean age at death of 55 years). This study [5], as well as the recent literature, reported that two thirds of MEN1 patients currently die from a MEN1-related cause, and in 40–45%, the principal cause is P-NET related. Thus, it remains essential to assess the presence and extent of any P-NET, both attempting to identify a F-P-NET in a MEN1 patient with symptoms as well as an asymptomatic NF-P-NET. A recent comparative study [107] demonstrated that EUS and MRI give complementary results for identifying tumors <2 and ≥2 cm; the cut-off of 2 cm was assessed in this study because it is recom-
mended in most guidelines for surgical exploration in MEN1 patients with NF-P-NETs or gastrinomas [107]. However, in this study, EUS missed 46% and MRI 17% of P-NETs ≥2 cm, and 16 and 19% of lesions >1 cm [107], whereas in other studies, both EUS and MRI detected lesions of this size [102, 108–111]. This study recommended that they should both be performed at the initial evaluation and that further studies need to be done to assess which to routinely perform on follow-up. At present, this is still unclear not only because the most sensitive method for detecting clinically important changes has not yet been defined, but also because the change rate that should lead to surgery has not yet been defined.

Whereas imaging with 68Ga-labeled somatostatin analogues with PET/CT is the most sensitive modality for localizing P-NETs and other NETs, its routine use in MEN1 patients is not yet defined. There is general agreement that it should be performed in any (P-)NET patient considered for surgery as well as patients with advanced disease to fully stage the tumor extent; however, it is not recommended as a screening tool in an asymptomatic patient.

MEN1 patients with insulinomas may need special localization methods (see the next section).

### Insulinoma Localization

In a small percentage of patients with insulinomas (<5–10%), all conventional imaging studies including EUS are negative [77, 90, 102, 112–114]. PET/CT scan with 68Ga-labeled somatostatin analogues is only positive in 25–31% of all patients with insulinomas [80, 90], so that it will only be helpful in a minority of these patients. Two other modalities continue to show promising results in these patients and should be considered: receptor scintigraphy with radiolabeled glucagon-like peptide 1 (GLP-1) receptor analogues is a sensitive method because insulinomas frequently overexpress this receptor [114–117]; however, this is available in only a few centers. Functional localization after selective intra-arterial injection of calcium with hepatic venous insulin gradients (IACIG) has proven to be a highly sensitive method to localize insulinomas and is positive in 90–100% of all cases [118, 119]; it should therefore be considered in patients where other imaging tests are negative (see fig. 3, insulinoma).

MEN1 patients with insulinoma present a special problem, since these patients often have multiple P-NETs imaged and most are NF-P-NETs, therefore singling out the insulinoma from the NF-P-NETs can be extremely difficult [7, 101, 120]. The use of IACIG can be particularly helpful in these patients and should be considered prior to surgery [14].

![Algorithm for treating NF-P-NETs](image)

**Insulinoma Localization**

In a small percentage of patients with insulinomas (<5–10%), all conventional imaging studies including EUS are negative [77, 90, 102, 112–114]. PET/CT scan with 68Ga-labeled somatostatin analogues is only positive in 25–31% of all patients with insulinomas [80, 90], so that it will only be helpful in a minority of these patients. Two other modalities continue to show promising results in these patients and should be considered: receptor scintigraphy with radiolabeled glucagon-like peptide 1 (GLP-1) receptor analogues is a sensitive method because insulinomas frequently overexpress this receptor [114–117]; however, this is available in only a few centers. Functional localization after selective intra-arterial injection of calcium with hepatic venous insulin gradients (IACIG) has proven to be a highly sensitive method to localize insulinomas and is positive in 90–100% of all cases [118, 119]; it should therefore be considered in patients where other imaging tests are negative (see fig. 3, insulinoma).

MEN1 patients with insulinoma present a special problem, since these patients often have multiple P-NETs imaged and most are NF-P-NETs, therefore singling out the insulinoma from the NF-P-NETs can be extremely difficult [7, 101, 120]. The use of IACIG can be particularly helpful in these patients and should be considered prior to surgery [14].

![Algorithm for treating NF-P-NETs](image)
Minimal Consensus Statement on RFTs

In addition to CT scan, MRI and EUS (as outlined in the previous guidelines [1]), recent studies showed that imaging with $^{68}$Ga-labeled somatostatin analogues with PET/CT is more sensitive and highly specific also for rare P-NETs [80, 83, 84] and it is therefore recommend it be performed to evaluate and stage the extent of disease.

$^{68}$Ga-labeled somatostatin analogues with PET/CT, if available, should be considered as the first-line diagnostic imaging method for staging in patients with rare P-NETs [83]. In case of rapid tumor growth in earlier diagnosed G1–G2 tumors, $^{18}$FDG-PET/CT may be considered to assess tumor burden and prognosis [106].

Tumor Classification, Staging, Histopathology and Genetic Sections

For P-NETs as well as other NETs, a number of TNM classification systems with grading have been developed (WHO 2010, ENETS , AJCC ) [39, 40, 121]. The WHO 2010 classification [122] was described in the 2011 guidelines [2].

Each of them has been shown to have important prognostic value for P-NET patients, and the routine use of one of these classification/grading systems is now essential to manage these patients [39–44, 121, 123–126]. Furthermore, a proper classification and grading system is important for selecting the correct treatment especially in patients with advanced or aggressive disease [127–130]. However, which system should be preferred is at present not completely established. In one large comparative study of 1,072 P-NET patients, the AJCC, WHO 2010 and ENETS TNM classification/grading systems were found to be independent predictors of survival in multivariate analysis; however, the ENETS TNM classification was superior to the AJCC/WHO 2010 classification/grading systems and more accurate [125]. Recent reports from studies on P-NETs suggest that a Ki-67 proliferation index threshold of 5% could better distinguish G1 from G2 tumors, which should be further explored [2, 122, 126, 131]. Because of the important predictive value of the proliferation index and its effect on treatment approaches, a biopsy for the reassessment of Ki-67 should be performed if a tumor demonstrates a more aggressive clinical course over time [132].

It has long been recognized that the development, presence and extent of liver metastasis are among the most important prognostic factors in patients with P-NETs; however, the role of lymph node metastasis as a prognostic factor has remained controversial. In the management of these patients, metastasis is an important aspect because it has an immediate influence on the type and extent of surgical procedure that should be performed. Recently, a number of studies have provided significant information on this point: the presence of lymph node metastasis can have important prognostic value as well as the extent of the lymph node metastasis or the number of positive lymph nodes [29–33, 35, 36, 133].

In recent years, various techniques of molecular biology allowed for a rapid progress in identifying factors important in the pathogenesis and/or prognosis of P-NET patients, especially whole-genome sequencing studies (i.e. the identification of genes for MEN1, DAXX/ATRX, mTOR pathway, etc.) [124, 134–138]. However, at present none of these are routinely used in the clinical management of P-NET patients or in the classification systems. Therefore, it is not recommended that any of these is routinely applied in P-NET patients, except in the case of a possible occurrence of an inherited syndrome (MEN1, VHL, etc.).

Recently, 5–10% of patients who clinically fit the criteria for MEN1 have been shown to not have mutations in the MEN1 gene; however, some of these patients (1.5%) have mutations in the cyclin-dependent kinase inhibitor gene, CDK1B, which encodes for p27kip1 (p27), a cyclin-dependent kinase inhibitor that regulates the transition of cells from the G1 to the S phase; these are now classified as MEN4 cases. Others have germline mutations of the cyclin-dependent kinase inhibitors p15, p18 and p21, which are a probable cause of MEN1 in approximately 1, 0.5 and 0.5% of all patients, respectively [7, 139, 140].

Pathology and Genetics

In all patients, P-NETs should be classified and graded using the current WHO 2010 classification and grading system. One recent study [141] showed a good correlation in grading between tissue samples and fine-needle aspirations at EUS; however, the use of EUS samples for grading needs further confirmation.

In patients with non-insulinoma P-NETs at the time of surgery, a routine dissection and harvesting of possible involved lymph nodes should be performed.

In those 5–10% of all patients with a MEN1 phenotype but no mutations in the MEN1 gene, it should be considered to perform genetic studies for mutations in cyclin-dependent kinase inhibitor genes (CDK1B, p15, p18, p21).

For metastatic NETs with unknown primary, the expression of Isl1 and PAX8 could indicate pancreatic origin [142, 143].
Surgery (fig. 3)

Surgical Treatment of ZES

General

There have been a number of surgical studies affecting the approach to ZES patients [30, 35, 94, 133, 144–147]. The role of surgery in ZES patients without MEN1 and with negative pre-operative imaging is controversial. A recent study [144] provided evidence that all sporadic ZES patients benefit from surgical exploration for cure, just as much as patients with presurgically identified tumors. In this study [144], the rate of disease-free patients after resection was higher in those with negative imaging than in those with positive imaging as well as the rate of disease-free survival after 20 years; however, tumors were found in >98% of patient irrespective of imaged tumors. Therefore, the recommendation is that all ZES patients without MEN1 who do not have a medical contraindication should undergo surgical exploration by a surgeon well-versed in the treatment of gastrinomas.

The importance of lymph node metastasis as a prognostic factor remains unclear with different studies giving different results. Recent studies on P-NET patients [29–33, 35, 36, 133] have reported that lymph node status and the number of positive nodes have important prognostic value. In addition to the prognostic value of lymph node metastasis, gastrinoma studies showed that resection can reduce the occurrence of persistent disease and improve survival [94, 128, 133] perhaps in some cases by resecting lymph node primary gastrinomas. This result supports the recommendation that the systematic removal of lymph nodes in the peritumoral area should be part of any gastrinoma operation.

The resection of pancreatic tumors with possible major vascular involvement is controversial both in the case of P-NETs and other pancreatic neoplasms. A recent study [148] demonstrated, in a group of P-NET patients (65% ZES patients) with CT evidence of major vascular involvement, that the P-NET could be safely removed in 91%, vascular resection was required in 19%; postoperatively, 30% were disease free and the 10-year survival rate was 62%. These results, combined with those of other recent reports [149–152], support the conclusion that surgical resection should be considered in P-NET patients with preoperative vascular involvement or invasion by a group well versed in this type of surgery.

The issue of surgical treatment of MEN1/ZES patients, as that of MEN1 patients with NF-P-NETs, continues to remain controversial [7, 22, 95, 96, 101, 147, 153, 154]. Additional studies demonstrate that MEN1/ZES patients, despite generally having multiple small duodenal gastrinomas, frequently with lymph node metastases, can be cured by extensive surgery such as pancreaticoduodenectomy. However, at present, this operation is not routinely recommended [1, 4, 155] because of its potential short- and long-term complications, the fact that patients with P-NETs ≤2 cm have an excellent long-term prognosis with survival rates of up to 100% at 15 years of follow-up [1, 4, 22, 153] and since, in MEN1/ZES patients, gastric hypersecretion can be well controlled medically [17, 46].

Additional Minimal Consensus Statement on Surgical Treatment of Gastrinomas

All patients with sporadic gastrinomas who do not have a medical contraindication should have surgical exploration by a surgeon well versed in the treatment of gastrinoma [144].

As part of any gastrinoma operation, the lymph nodes in the peritumoral area should be systematically removed so that they can be assessed for their prognostic value and as a possibility of increasing the cure rate.

Surgical resection in P-NET patients with preoperative vascular involvement or invasion should be considered and done by a group well versed in this type of surgery.

In MEN1/ZES patients with P-NETs ≤2 cm or with NF-P-NETs on imaging studies, routine surgical exploration is still not generally recommended. In patients with P-NETs >2 cm, enucleation at surgery remains the generally recommended surgical procedure, while pancreaticoduodenectomy is reserved for specific selected cases [1, 22, 95, 101, 153, 155].

Surgical Treatment of Insulinomas

General

Many recent studies demonstrate that, both in adults and in children, surgical exploration results in a high cure rate (98–100%) [37, 156–159]. In most cases, enucleation of the insulinoma is possible; while a more extensive resection is required in the remaining patients [37, 156–159]. A recent systematic review [160] provides support for a laparoscopic approach which is not only safe and associated with reduced hospitalization stay but also achieves cure rates comparable to open surgery. In MEN1 patients with insulinomas (25%), surgery should also be performed when metastatic disease is not present (90–97%), and enucleation or limited resection remain the procedure of choice [101, 120]. A laparoscopic approach has been successful in a selected group of MEN1 patients with imaged insulinomas [161–163].

The use of ablative therapy either endoscopically or percutaneously with radiological guidance has also been reported to be successful. EUS-guided ablation using eth-
anol injections or CT-guided radiofrequency ablation has been reported to be successful in insulinoma patients with either sporadic disease or MEN1 [37, 156–159].

Additional Minimal Consensus Statement on Surgical Treatment of Insulinomas

Surgical exploration for possible cure should be performed in all insulinoma patients with or without MEN1 in the absence of non-resectable metastatic disease. A laparoscopic approach is generally recommended in patients with sporadic disease with imaged tumors [163]. In patients with a localized insulinoma who are not thought to be candidates for surgery, the use of ablative therapy either endoscopically or percutaneously with radiological guidance has been reported to be successful but further data are required. EUS-guided ablation using ethanol injections or CT-guided radiofrequency ablation has also been reported to be successful [37, 156–159].

Additional Minimal Consensus Statement on Surgical Treatment of NF-P-NETs

Attempted curative resection is still recommended for all patients with RFTs or very rare F-P-NETs in the absence of non-resectable metastatic disease [1, 2, 155, 159]. A laparoscopic approach can be used in localized imaged RFTs [1, 163–165]. In MEN1 patients with P-NETs ≤2 cm or with NF-P-NETs on imaging studies, routine surgical exploration is still not generally recommended. In patients with P-NETs >2 cm, enucleation/local resection at surgery is possible in many patients, while pancreaticoduodenotomy is reserved for specific selected cases [1, 2, 155, 159].

Surgical Treatment of NF-P-NETs versus Observation

Several studies have explored the safety and feasibility of a non-operative management for asymptomatic sporadic NF-P-NETs ≤2 cm, especially when a major pancreatic resection is required. A conservative approach seems to be safe as the majority of the observed tumors did not show any significant changes during follow-up [37, 166, 167]. However, follow-up data are needed to guarantee the safety of this policy. The long-term outcome of VHL patients with resected P-NETs is better than that of patients with sporadic NF-P-NETs, and lesions ≤15 mm in size can be safely managed non-operatively [168]. Moreover, a recent paper reported that NF-P-NETs in VHL patients demonstrated a non-linear growth pattern, which included periods of no growth and apparent decrease in size by imaging. Tumor density may offer a specific diagnostic tool for malignant disease [169]. Recent data have advocated for extended surgical resection of advanced P-NETs [149, 169]. In this context, a simultaneous surgical resection of liver metastases and primary tumor could be performed with low mortality and morbidity rates as suggested in a recent small study [169]. However, simultaneous pancreaticoduodenectomy and major hepatectomy should be avoided due to the high morbidity and mortality rates [169].

Medical Therapy of F-P-NETs (fig. 3)

Medical Treatment of ZES

General

A number of publications have reviewed various aspects of medical therapy of gastric acid hypersecretion and other features of ZES since the 2011 guidelines [17, 46, 55]. PPIs remain the drugs of choice to control acid hypersecretion in all patients who can take oral medication with once or twice a day dosing. PPIs appear to remain among the safest drugs for long-term use with minimal side effects. Recent studies have demonstrated that hypomagnesemia can develop in patients taking PPIs; it is a PPI drug class effect [170–173]. A number of epidemiological studies have reported an increased incidence of bone fracture in patients on long-term PPI treatment without ZES, although this finding is disputed in other studies. Monitoring for the development of vitamin B12 deficiency in ZES patients on long-term PPIs continues to be advised especially in the elderly or in patients with previously reported malabsorption [170, 174–176].

The effect of curative resection on acid hypersecretion in ZES patients has not been systematically studied until recently, and its management is controversial. A study of 50 ZES patients [177] demonstrated that despite being cured 62% suffered from hypersecretion and in 28% acid output remained very high (basal acid output >2.5 normal); this lasted for up to 8 years. These patients were found to show increased postoperative ECL changes and activity, but the mechanism was not clearly defined. This study [177] concluded that a high proportion of ZES patients undergoing a surgical ‘cure’ continue to require gastric acid-suppressive treatment, and thus they should be carefully monitored and their PPIs should not be abruptly stopped postoperatively.

Minimal Consensus Statement on Medical Treatment of ZES

Acid hypersecretion in ZES patients should be controlled at all times, with the drugs of choice being PPIs (once or twice daily) [17, 46, 57]. Surveillance involves assessing continued acid control, monitoring for vitamin B12 deficiency and being aware
that hypomagnesemia is more frequent in patients taking PPIs as it is a PPI drug class effect. Patients who are surgically cured may continue to suffer from gastric acid hypersecretion and require frequent monitoring, and most (60%) require continued antisecretory drugs, although usually at lower doses.

Medical Treatment of Insulinomas

**General**

Prior to surgery and in the small group with malignant disease (<10%), besides treating hypoglycemia with frequent small meals and diazoxide, approximately 30–50% respond to somatostatin analogues, although the patients need to be carefully monitored because a proportion may get worse on this treatment [17, 128, 178–182]. Numerous recent reports have demonstrated that the mTOR inhibitor everolimus is effective in these patients with malignant insulinomas at controlling hypoglycemia [17, 128, 179–181, 183], and in one case, sunitinib was also shown to be effective [184]. Antitumor treatment with peptide receptor-targeted radiotherapy (PRRT) or bland or chemoembolization can also control hypoglycemia in patients with malignant insulinomas [128, 185–187].

**Minimal Consensus Statement on Medical Treatment of Insulinomas**

Surgery remains the preferred treatment whenever possible, but prior to surgery, recurrent cases and patients with malignant insulinomas need medical treatment. In addition to diazoxide, frequent small meals, somatostatin analogues and the mTOR inhibitor everolimus have been demonstrated to be effective in controlling hypoglycemia in an increasing number of reports. Sunitinib has also been effective in a few patients, and in malignant insulinomas, PRRT or chemoembolization can help control hypoglycemia.

Medical Treatment of RFTs

**General**

Somatostatin analogues remain the treatment of choice for the hormone-excess state in RFTs prior to surgery or if resection cannot be performed. There are recent reports of their effectiveness in PTHrPomas, ACTHomas, VIPomas, GRFomas and other RFTs [18, 182, 188–191].

Medical Treatment of Advanced Metastatic P-NETs

The medical treatment of advanced metastatic P-NETs is covered in a special chapter on Metastatic NETs in this issue [192].

Locoregional Ablative Therapy

**Selective Embolization**

Hepatic artery embolization and hepatic artery chemotherapy embolization are contraindicated in patients who have undergone Whipple’s procedure [3, 128].

**Medical Treatment**

For the medical treatment, see the revision of the ENETS 2011 guidelines for the management of distant metastases of intestinal, pancreatic and bronchial NETs and NETs of unknown origin [3; 192, this issue].

**Peptide Receptor-Targeted Radiotherapy**

Promising data have evolved with regard to PRRT using $^{90}$Y-DOTATOC or $^{177}$Lu-DOTATATE in the treatment of NETs including P-NETs with distant metastases [149, 193–195]. PRRT can be considered in both F-P-NETs and NF-P-NETs with high and homogenous expression of somatostatin receptors irrespective of the site of the primary tumor. Based on the results from phase II trials, more than 1,000 patients have been treated with PRRT in Europe with complete or partial objective responses in up to 30–40% and a progression-free survival of 17–40 months [149, 193–195]. The results from prospective randomized trials comparing PRRT with other therapeutic options are lacking, but a phase III trial comparing PRRT with octreotide is ongoing (NETTER-1, NCT01578239). PRRT is still considered investigational and its implementation must comply with national legislation and ethical guidelines [196].

For treatment with PRRT, the following requirements should be fulfilled: (1) histopathologically proven NET; (2) high somatostatin receptor expression (sstr2) determined by functional imaging with SRS or $^{68}$Ga-DOTA-peptide PET/CT; (3) the Karnofsky index should be $>60\%$ or ECOG $<2$, and (4) WHO grade 1/2, and Ki-67 $\leq 20\%$ [196].

Dose-limiting organs are the kidneys and the bone marrow. For PRRT with $^{90}$Y-labeled peptide, which is considered more nephrotoxic, normal renal function is required. For PRRT with $^{177}$Lu-labeled peptide, mild renal impairment can be tolerated, but the glomerular filtration rate should be at least 60% of the mean age-adjusted normal values. Required liver function parameters are: total bilirubin $<3$ ULN, albumin $>30$ g/l and normal pharmacokinetics. The bone marrow should at least have the following reference values: WBC $>3 \times 10^9$; platelets $>75 \times 10^9$ for $^{177}$Lu-DOTATATE or $90 \times 10^9$ for $^{90}$Y-DOTATOC; hemoglobin $>5$ mmol/l (8 g/dl). The
minimum requirements for PRRT are described in separate consensus guidelines [196, 197].

There are different research protocols in use, and there is no standard with regard to the number of cycles or activity of cycles with PRRT. The interval between courses should be at least 6 weeks and may be longer if toxicity occurs. Individualized treatment guided by dosimetry of kidneys and bone is being explored [198].

The treatment is generally well tolerated, but serious side effects may occur, including severe bone marrow disease (acute myelogenous leukemia, myelodysplastic syndrome) both in patients with and without previous chemotherapy. Kidney failure has been reported, especially with 90Y-based treatment, but protective amino acid infusions are routinely given to avoid this complication. Patients with pending liver failure are not candidates for PRRT.

PRRT is still not considered as first-line treatment, but it can be recommended in advanced NET after failure of medical treatment and should be used within clinical study protocols.

Follow-Up during Treatment

Patient follow-up during treatment should include the measurement of biochemical markers and conventional imaging (CT and/or MRI) every 3–9 months in patients with grade 1 and grade 2 tumors. The interval between assessments can be increased if the disease is stable (especially for indolent grade 1 tumors). If positive, somatostatin receptor imaging should be repeated every 2 years or earlier if progression is suspected.

Please also refer to the consensus guideline updates for other gastroenteropancreatic NETs [192, 199–203, this issue].

Appendix 1

RFTs and Very Rare F-P-NETs

Even though all RFTs are considered as one group, they actually comprise two different groups as has recently been pointed out [17]: RFTs (VIPoma, glucagonoma, GRFoma, ACTHomas and RFTs causing carcinoid syndrome or hypercalcemia – PTHrPomas) together with SSomas, for which there are more than 100 cases described [188], and a second group, the very rare F-P-NETs (P-NETs secreting renin, luteinizing hormone, erythropoietin, GLP-1, insulin-like growth factor 2 and CCK) [1], for which 1–5 cases have been described [17, 23, 204] (table 1). The only new functional syndromes described since the 2011 guidelines are the ectopic secretion of GLP-1 [204] and CCK (CCKoma) [23] from a P-NET. The GLP-1-secreting P-NET caused both diabetes and hypoglycemic symptoms, which is similar to what had been previously reported in a patient with an ovarian stromal NET secreting GLP-1 [205]. Patients with functional CCKomas had not been previously described until recently, when a single well-described case was documented [23] in a patient who had diarrhea, cholelithiasis, suffered from severe weight loss and a bleeding peptic ulcer with normal FSG levels but increased plasma CCK levels (>100-fold). Thus, this patient mimics many of the features of a ZES patient with normal fasting gastrin levels [23].

Not listed in table 1 as F-P-NET syndromes are P-NETs secreting calcitonin, neurotensin, pancreatic polypeptide and ghrelin, all of which have been proposed to be functional syndromes in some papers [17, 206, 207]. However, in numerous series, many asymptomatic P-NET patients have been described with elevated levels of these hormones, and at present, most authorities continue not to accept these as distinct F-P-NET syndromes [17, 206].

Recently, a new syndrome has been described involving the development of duodenal SSomas, paragangliomas and the presence of polycythemia, with gain of function HIF2A mutations in the tumors but not the germline [208]. A possible new genetic disorder, Mahvash disease, has been reported which is caused by inactivating mutations of the human glucagon receptor and which is associated with the development of α-cell hyperplasia, hyperglucagonemia and the development of NF-P-NETs [209]. This disorder can be reproduced in glucagon receptor-deficient mice [209, 210]. At present, it is unknown if this disease is inherited and expressed in different generations.

Appendix 2

All Other Vienna Consensus Conference Participants

Anlauf, M. (Institut für Pathologie und Zytologie, St. Vincenz Krankenhaus, Limburg, Germany); Baudin, E. (Institut Gustave Roussy, Villejuif, France); Costa, F. (Centro de Oncologia, Hospital São Paulo, Brazil); Cwikla, J.B. (Department of Radiology, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland); De Herder, W.W. (Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands); Delle Fave, G. (Department of Digestive and Liver Disease, Ospedale Sant’Andrea, Rome, Italy); Ferolla, P. (NET Center, Umbria Regional Cancer Network, Università degli Studi di Perugia, Perugia, Italy); Ferone, D. (Department of Endocrine and Metabolic Sciences, University of Genoa, Genoa, Italy); Garcia-Carbonero, R. (Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain); Gross, D. (Department of Endocrinology and Metabolism, Hadasah University Hospital, Mevasseret Tsion, Israel); Ito, T. (Pancreatic Diseases Branch, Kyushu University Hospital, Fukuoka, Japan); Kelestimur, F. (Department of Endocrinology, Erçiyes University Medical School, Kayseri, Turkey); Knigge, U. (Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark); Krenning, E. (Department of Internal Medicine, Division of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands); Niederle, B. (Department of Surgery, Medical University of Vienna, Vienna, Austria); Öberg, K. (Department of Medical Sciences, Endocrine Oncology Unit, University Hospital, Uppsala, Sweden); O’Connor, J. (Department of Clinical Oncology, Insti-
9 Falconi M, Bartsch DK, Eriksson B, et al: In-
11 Levy-Bohbot N, Merle C, Goudet P, et al: Diag-
12 Ruszniewski, P. (Department of Gastroenterology, Beaujon Hos-
13 NHS Trust, Hampshire, UK); Raymond, E. (Oncologie Médicale,
14 magie, J.K. (Gastroenterology Department, Hampshire Hospitals
15 Ito T, Igarashi H, Uehara H, et al: Causes of
16 Lee LC, Grant CS, Salomao DR, et al: Small,
18 Kamp K, Feelders RA, van Adrichem RC, et
19 Garbrecht N, Anlauf M, Schmitt A, et al: So-
20 Berna MJ, Hoffmann KM, Serrano J, et al: Se-
22 Halfdanarson TR, Rabe KG, Rubin J, et al:
23 Rehfeld JF, Federspiel B, Bardram L: A neuro-
26 FGagnon, P., et al: Enzymatic degradation of
27 HO, et al: Enzymatic degradation of
28 Fujimura, M., et al: Enzymatic degradation of
29 Vile, R.G., et al: Enzymatic degradation of
30 Anna, M., et al: Enzymatic degradation of
31 Wiberg, C., et al: Enzymatic degradation of
32 Gallo, M., et al: Enzymatic degradation of
33 Carreira, C., et al: Enzymatic degradation of
34 Gallo, M., et al: Enzymatic degradation of
35 Gallo, M., et al: Enzymatic degradation of
36 Gallo, M., et al: Enzymatic degradation of
37 Gallo, M., et al: Enzymatic degradation of
38 Gallo, M., et al: Enzymatic degradation of
39 Gallo, M., et al: Enzymatic degradation of
40 Gallo, M., et al: Enzymatic degradation of
41 Gallo, M., et al: Enzymatic degradation of
42 Gallo, M., et al: Enzymatic degradation of
43 Gallo, M., et al: Enzymatic degradation of
44 Gallo, M., et al: Enzymatic degradation of
45 Gallo, M., et al: Enzymatic degradation of
46 Gallo, M., et al: Enzymatic degradation of
47 Gallo, M., et al: Enzymatic degradation of
48 Gallo, M., et al: Enzymatic degradation of
49 Gallo, M., et al: Enzymatic degradation of
50 Gallo, M., et al: Enzymatic degradation of
51 Gallo, M., et al: Enzymatic degradation of
52 Gallo, M., et al: Enzymatic degradation of
53 Gallo, M., et al: Enzymatic degradation of
54 Gallo, M., et al: Enzymatic degradation of
55 Gallo, M., et al: Enzymatic degradation of
56 Gallo, M., et al: Enzymatic degradation of
57 Gallo, M., et al: Enzymatic degradation of
58 Gallo, M., et al: Enzymatic degradation of
59 Gallo, M., et al: Enzymatic degradation of
60 Gallo, M., et al: Enzymatic degradation of
61 Gallo, M., et al: Enzymatic degradation of
62 Gallo, M., et al: Enzymatic degradation of
63 Gallo, M., et al: Enzymatic degradation of
64 Gallo, M., et al: Enzymatic degradation of
65 Gallo, M., et al: Enzymatic degradation of
66 Gallo, M., et al: Enzymatic degradation of
67 Gallo, M., et al: Enzymatic degradation of
68 Gallo, M., et al: Enzymatic degradation of
69 Gallo, M., et al: Enzymatic degradation of
70 Gallo, M., et al: Enzymatic degradation of
71 Gallo, M., et al: Enzymatic degradation of
72 Gallo, M., et al: Enzymatic degradation of
73 Gallo, M., et al: Enzymatic degradation of
74 Gallo, M., et al: Enzymatic degradation of
75 Gallo, M., et al: Enzymatic degradation of
76 Gallo, M., et al: Enzymatic degradation of
77 Gallo, M., et al: Enzymatic degradation of
78 Gallo, M., et al: Enzymatic degradation of
79 Gallo, M., et al: Enzymatic degradation of
80 Gallo, M., et al: Enzymatic degradation of
81 Gallo, M., et al: Enzymatic degradation of
82 Gallo, M., et al: Enzymatic degradation of
83 Gallo, M., et al: Enzymatic degradation of
84 Gallo, M., et al: Enzymatic degradation of
85 Gallo, M., et al: Enzymatic degradation of
86 Gallo, M., et al: Enzymatic degradation of
87 Gallo, M., et al: Enzymatic degradation of
88 Gallo, M., et al: Enzymatic degradation of
89 Gallo, M., et al: Enzymatic degradation of
90 Gallo, M., et al: Enzymatic degradation of
91 Gallo, M., et al: Enzymatic degradation of
92 Gallo, M., et al: Enzymatic degradation of
93 Gallo, M., et al: Enzymatic degradation of
94 Gallo, M., et al: Enzymatic degradation of
95 Gallo, M., et al: Enzymatic degradation of
96 Gallo, M., et al: Enzymatic degradation of
97 Gallo, M., et al: Enzymatic degradation of
98 Gallo, M., et al: Enzymatic degradation of
99 Gallo, M., et al: Enzymatic degradation of
100 Gallo, M., et al: Enzymatic degradation of
101 Gallo, M., et al: Enzymatic degradation of
102 Gallo, M., et al: Enzymatic degradation of
103 Gallo, M., et al: Enzymatic degradation of
104 Gallo, M., et al: Enzymatic degradation of
105 Gallo, M., et al: Enzymatic degradation of
106 Gallo, M., et al: Enzymatic degradation of
107 Gallo, M., et al: Enzymatic degradation of
108 Gallo, M., et al: Enzymatic degradation of
109 Gallo, M., et al: Enzymatic degradation of
110 Gallo, M., et al: Enzymatic degradation of
111 Gallo, M., et al: Enzymatic degradation of
112 Gallo, M., et al: Enzymatic degradation of
113 Gallo, M., et al: Enzymatic degradation of
114 Gallo, M., et al: Enzymatic degradation of
115 Gallo, M., et al: Enzymatic degradation of
116 Gallo, M., et al: Enzymatic degradation of
117 Gallo, M., et al: Enzymatic degradation of
118 Gallo, M., et al: Enzymatic degradation of
119 Gallo, M., et al: Enzymatic degradation of
120 Gallo, M., et al: Enzymatic degradation of
121 Gallo, M., et al: Enzymatic degradation of
122 Gallo, M., et al: Enzymatic degradation of
123 Gallo, M., et al: Enzymatic degradation of
124 Gallo, M., et al: Enzymatic degradation of
125 Gallo, M., et al: Enzymatic degradation of
126 Gallo, M., et al: Enzymatic degradation of
127 Gallo, M., et al: Enzymatic degradation of
128 Gallo, M., et al: Enzymatic degradation of
129 Gallo, M., et al: Enzymatic degradation of
130 Gallo, M., et al: Enzymatic degradation of
131 Gallo, M., et al: Enzymatic degradation of
132 Gallo, M., et al: Enzymatic degradation of
133 Gallo, M., et al: Enzymatic degradation of
134 Gallo, M., et al: Enzymatic degradation of
135 Gallo, M., et al: Enzymatic degradation of
136 Gallo, M., et al: Enzymatic degradation of
137 Gallo, M., et al: Enzymatic degradation of
138 Gallo, M., et al: Enzymatic degradation of
139 Gallo, M., et al: Enzymatic degradation of
140 Gallo, M., et al: Enzymatic degradation of
141 Gallo, M., et al: Enzymatic degradation of
142 Gallo, M., et al: Enzymatic degradation of
143 Gallo, M., et al: Enzymatic degradation of
144 Gallo, M., et al: Enzymatic degradation of


F-P-NETs and NF-P-NETs


